Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defactinib ADME study in healthy males
NCT02913716Phase 1Completed
- Sponsor
- Verastem Oncology
- Start
- Aug 2015
- Primary completion
- Sep 2015
01
Overview
Phase 1, open-label trial of defactinib in mesothelioma and solid tumor, sponsored by Verastem Oncology. Primary endpoints: Urine amount excreted at 168 hours, Urine fraction of the dose excreted at 168 hours and 1 more. Started Aug 2015; status: completed.
02
Drugs
defactinib
03
Conditions
mesotheliomasolid tumor
Beyond the preview
Go deeper on NCT02913716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913716.